Entheon Biomedical
  • CSE:ENBI
  • OTC:ENTBF
  • ABOUT ENTHEON
  • REASONS TO BELIEVE
  • TEAM
  • INVESTORS
    • SHARE STRUCTURE
    • STOCK INFORMATION
    • FINANCIAL STATEMENTS
    • PRESS RELEASES & NEWS
  • CONTACT
Select Page
When Will Psychedelics be Legal in the United States?

When Will Psychedelics be Legal in the United States?

by Entheogen Biomedical | Oct 30, 2020 | Industry News

With all eyes on the US election, we are sure that those in the psychedelic medicine sphere wonder what this could mean for the future of psychedelic medicine in the United States.  The US is home to many crucial networks and institutes that are moving the...
Canada Calls for Reformative Action in the Opioid Crisis

Canada Calls for Reformative Action in the Opioid Crisis

by Entheogen Biomedical | Oct 27, 2020 | Industry News

Worldwide, substance use disorders are on the rise, causing a high financial and social cost, yet the current model helps only a fraction of those suffering. Substance use disorders have exacerbated overcrowding of the healthcare system, which has forced policymakers...
The steep price of not treating Canada’s opioid crisis

The steep price of not treating Canada’s opioid crisis

by Entheogen Biomedical | Sep 25, 2020 | Industry News

The toll of the opioid crisis begins in the home and community, destroying lives, picking away at the very fabric which holds us together as a people. From there, the collateral damage extends into the economy and our civic institutions, imposing a financial and...
Opioid Crisis in Canada—the Communities it Disproportionately Affects

Opioid Crisis in Canada—the Communities it Disproportionately Affects

by Entheogen Biomedical | Aug 27, 2020 | Industry News

Written by Jessica Cadoch Opioids don’t discriminate—opioid misuse affects all Canadians On August 12, we wrote about the current opioid crisis and the uptick on opioid-related overdoses and deaths in Canada. This crisis does not discriminate against...
Overview of the worsening opioid crisis in Canada

Overview of the worsening opioid crisis in Canada

by Entheogen Biomedical | Aug 12, 2020 | Industry News

Written by Jessica Cadoch Oxycodone, Codeine, Morphine and Heroin are all classified opiates. These substances are procedurally offered by medical experts as painkillers and seek to relieve patients from deep suffering.  However, these substances are also highly...
We can no longer ignore the potential of psychedelic drugs to treat depression

We can no longer ignore the potential of psychedelic drugs to treat depression

by Entheogen Biomedical | Jun 18, 2020 | Industry News

The world is experiencing a devastating physical health emergency. But the coronavirus pandemic has also seen a renewed focus on our psychological wellbeing. Loneliness, uncertainty and grief may be intensifying an already acute mental health crisis, and in the US...
« Older Entries

Recent Posts

  • Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
  • Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial
  • Entheon Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange
  • When Will Psychedelics be Legal in the United States?
  • MPV annonce l’approbation conditionnelle de sa transaction avec Entheon Biomedical Corp. par le CSE

Recent Comments

    Archives

    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • June 2020
    • May 2020
    • April 2020
    • February 2020
    • December 2019
    • November 2019
    • July 2019
    • April 2019
    • December 2018
    • February 2018
    • January 2018

    Categories

    • Company News
    • Industry News
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Entheon Biomedical 2020 © All rights reserved | Website by S3 Communications | Terms & Privacy